OBJECTIVES: Deficiencies of the anion exchanger SLC4A2 are thought to play a pathogenic role in primary biliary cirrhosis (PBC), as the evidenced by decreased expression and activity in PBC patients and development of disease features in SLC4A2 knockout mice. We hypothesized that genetic variation in SLC4A2 might influence this pathogenic contribution. Thus, we aimed to perform a comprehensive assessment of SLC4A2 genetic variation in PBC using a linkage disequilibrium (LD)-based haplotype-tagging approach. METHODS: Twelve single nucleotide polymorphisms (SNPs) across SLC4A2 were genotyped in 409 PBC patients and 300 controls and evaluated for association with disease, as well as with prior orthotopic liver transplant and antimitochondrial antibody (AMA) status among the PBC patients, both individually and as inferred haplotypes, using logistic regression. RESULTS: All SNPs were in Hardy-Weinberg equilibrium. No associations with disease or liver transplantation were detected, but two variants, rs2303929 and rs3793336, were associated with negativity for antimitochondrial antibodies among the PBC patients. CONCLUSIONS: The common genetic variation of SLC4A2 does not directly affect the risk of PBC or its clinical outcome. Whether the deficiency of SLC4A2 expression and activity observed earlier in PBC patients is an acquired epiphenomenon of underlying disease or is because of heritable factors in unappreciated regulatory regions remains uncertain. Of note, two SLC4A2 variants appear to influence AMA status among PBC patients. The mechanisms behind this finding are unclear.
OBJECTIVES: Deficiencies of the anion exchanger SLC4A2 are thought to play a pathogenic role in primary biliary cirrhosis (PBC), as the evidenced by decreased expression and activity in PBCpatients and development of disease features in SLC4A2 knockout mice. We hypothesized that genetic variation in SLC4A2 might influence this pathogenic contribution. Thus, we aimed to perform a comprehensive assessment of SLC4A2 genetic variation in PBC using a linkage disequilibrium (LD)-based haplotype-tagging approach. METHODS: Twelve single nucleotide polymorphisms (SNPs) across SLC4A2 were genotyped in 409 PBCpatients and 300 controls and evaluated for association with disease, as well as with prior orthotopic liver transplant and antimitochondrial antibody (AMA) status among the PBCpatients, both individually and as inferred haplotypes, using logistic regression. RESULTS: All SNPs were in Hardy-Weinberg equilibrium. No associations with disease or liver transplantation were detected, but two variants, rs2303929 and rs3793336, were associated with negativity for antimitochondrial antibodies among the PBCpatients. CONCLUSIONS: The common genetic variation of SLC4A2 does not directly affect the risk of PBC or its clinical outcome. Whether the deficiency of SLC4A2 expression and activity observed earlier in PBCpatients is an acquired epiphenomenon of underlying disease or is because of heritable factors in unappreciated regulatory regions remains uncertain. Of note, two SLC4A2 variants appear to influence AMA status among PBCpatients. The mechanisms behind this finding are unclear.
Authors: Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson Journal: Am J Hum Genet Date: 2003-12-15 Impact factor: 11.025
Authors: Carlo Selmi; David L Balkwill; Pietro Invernizzi; Aftab A Ansari; Ross L Coppel; Mauro Podda; Patrick S Leung; Thomas P Kenny; Judy Van De Water; Michael H Nantz; Mark J Kurth; M Eric Gershwin Journal: Hepatology Date: 2003-11 Impact factor: 17.425
Authors: Ahmad S Abdulkarim; Lydia M Petrovic; Woong R Kim; Paul Angulo; Ricardo V Lloyd; Keith D Lindor Journal: J Hepatol Date: 2004-03 Impact factor: 25.083
Authors: Carlo Selmi; Marlyn J Mayo; Nancy Bach; Hiromi Ishibashi; Pietro Invernizzi; Robert G Gish; Stuart C Gordon; Harlan I Wright; Bruce Zweiban; Mauro Podda; M Eric Gershwin Journal: Gastroenterology Date: 2004-08 Impact factor: 22.682
Authors: Saida Melero; Carlo Spirlì; Akos Zsembery; Juan F Medina; Ruth E Joplin; Elena Duner; Massimo Zuin; James M Neuberger; Jesús Prieto; Mario Strazzabosco Journal: Hepatology Date: 2002-06 Impact factor: 17.425
Authors: Lizhe Xu; Zhiwei Shen; Linsheng Guo; Brent Fodera; Adrian Keogh; Ruth Joplin; Barbara O'Donnell; James Aitken; William Carman; James Neuberger; Andrew Mason Journal: Proc Natl Acad Sci U S A Date: 2003-06-27 Impact factor: 12.779
Authors: Saif Abu-Mouch; Carlo Selmi; Gordon D Benson; Thomas P Kenny; Pietro Invernizzi; Massimo Zuin; Mauro Podda; Lorenzo Rossaro; M Eric Gershwin Journal: Clin Dev Immunol Date: 2003 Jun-Dec
Authors: Junwei Huang; Jiajie Shan; Dusik Kim; Jie Liao; Alexandra Evagelidis; Seth L Alper; John W Hanrahan Journal: J Physiol Date: 2012-07-16 Impact factor: 5.182
Authors: Jesús M Banales; Elena Sáez; Miriam Uriz; Sarai Sarvide; Aura D Urribarri; Patrick Splinter; Pamela S Tietz Bogert; Luis Bujanda; Jesús Prieto; Juan F Medina; Nicholas F LaRusso Journal: Hepatology Date: 2012-07-10 Impact factor: 17.425
Authors: Guanghua Rong; Renqian Zhong; Ana Lleo; Patrick S C Leung; Christopher L Bowlus; Guo-Xiang Yang; Chen-Yen Yang; Ross L Coppel; Aftab A Ansari; Dean A Cuebas; Howard J Worman; Pietro Invernizzi; Gregory J Gores; Gary Norman; Xiao-Song He; M Eric Gershwin Journal: Hepatology Date: 2011-07 Impact factor: 17.425